| |SEPTEMBER 20239GARDP INKS SUBLICENSE AGREEMENT WITH ORCHID PHARMA TO PRODUCE ANTIBIOTIC FOR GRAM-NEGATIVE INFECTIONSNOVABAY PHARMA ANNOUNCES AN AGREEMENT WITH BIOSTEM TO COMMERCIALIZE AMNIOTIC TISSUE ALLOGRAFTThe Global Antibiotic Research and Development Partnership (GARDP) and India-based Orchid Pharma Ltd (Orchid) have agreed to manufacture cefiderocol, an antibiotic used to treat certain Gram-negative infections. This agreement is a vital milestone in Shionogi & Co. Ltd. (Shionogi), GARDP, and the Clinton Health Access Initiative (CHAI)'s ambitious endeavor to provide cefiderocol access in a number of mostly low- and middle-income countries.Infections caused by Gram-negative bacteria include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis. Gram-negative bacteria are resistant to several medications and are becoming increasingly resistant to the majority of current antibiotics, according to the Centers for Disease Control and Prevention (CDC). Furthermore, the new agreement will expedite drug availability for tens of thousands of patients in areas with significant antimicrobial resistance (AMR).The project, which began in June of last year, represents a novel strategy for overcoming worldwide disparities in fair access to critical antibiotics."Even though populations in low-and middle-income countries face a high burden of death from drug-resistant bacterial infections, their access to antibiotics with activity against resistant bacteria is usually delayed by more than a decade. That situation may worsen given that the number of serious, potentially life-threatening, infections due to carbapenem-resistant bacteria has been growing across multiple regions, including South Asia and Latin America," the organisation said in a statement on Tuesday. PONovaBay Pharmaceuticals, Inc. and BioStem Technologies, Inc. have announced an agreement under which NovaBay has been awarded the exclusive right to commercialize BioStem Technologies' Amniotic Tissue Allograft, which is designed to be used as a protective covering during ocular surface restoration.Amniotic Tissue Allograft creates a protective environment or coating for corneal and conjunctival restoration, allowing the ocular surface to mend. NovaBay plans to market the prescription-only medicine as Avenova Allograft in order to capitalize on its Avenova eyecare brand and encourage use with other Avenova products. Medicare will cover medically required operations involving the Avenova Allograft.Human amniotic membrane generated from placenta is a rich source of pro-healing growth factors and anti-inflammatory cytokines. Amniotic allografts have been utilized successfully in regenerative medicine for more than a century, and dehydrated human amniotic membrane is still commonly employed as an ocular covering. Avenova Allograft is the only optic allograft made with BioStem Technologies' proprietary six-step BioREtain® process, which retains the placental tissue's natural integrity. This new NovaBay-branded product will compete in the global ophthalmology amniotic membrane market, which is predicted to be worth $403.6 million in 2022 and to increase at a 9.8% annual rate between 2023 and 2030. PO
< Page 8 | Page 10 >